{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 2-[4-[(''E'')-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
| image = Enclomifene.png
| width = 250px

<!--Clinical data-->
| tradename = Androxal
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 15690-57-0
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 1548953
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 1265967
| UNII = R6D2UI4FLS
| KEGG = D08910
| ChEBI = 3752
| ChEMBL = 954

<!--Chemical data-->
| C=26 | H=28 | Cl=1 | N=1 | O=1
| molecular_weight = 405.966 g/mol
| SMILES = CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
| StdInChI_Ref = 
| StdInChI = 1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
| StdInChIKey_Ref = 
| StdInChIKey = GKIRPKYJQBWNGO-OCEACIFDSA-N
| synonyms = Enclomiphene; ''cis''-Clomifene; Cisclomiphene; (''E'')-Clomifene; RMI-16289; Enclomid; Enclomifene citrate; Enclomiphene citrate
}}

'''Enclomifene''' ({{abbrlink|INN|International Nonproprietary Name}}) (tentative brand name '''Androxal'''), or '''enclomiphene''' ({{abbrlink|USAN|United States Adopted Name}}), is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group that is under development for the treatment of male [[hypogonadism]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA298|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=298–}}</ref><ref name="MortonHall1999">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA79|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=79–}}</ref><ref name="AdisInsight">http://webcache.googleusercontent.com/search?q=cache:rTob_FmpvpUJ:adisinsight.springer.com/drugs/800019625+&cd=1&hl=en&ct=clnk&gl=us</ref><ref name="pmid19204885">{{cite journal | vauthors = Hill S, Arutchelvam V, Quinton R | title = Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men | journal = IDrugs | volume = 12 | issue = 2 | pages = 109–19 | year = 2009 | pmid = 19204885 | doi = | url = https://www.researchgate.net/profile/Richard_Quinton/publication/23995306_Enclomiphene_an_estrogen_receptor_antagonist_for_the_treatment_of_testosterone_deficiency_in_men/links/02bfe50e467a559bf9000000.pdf}}</ref> As of December 2016, it is in the pre-registration phase of development and is under review by the {{abbrlink|FDA|Food and Drug Administration}} in the [[United States]] and the {{abbrlink|EMA|European Medicines Agency}} in [[Europe]].<ref name="AdisInsight" />

Enclomifene acts by [[receptor antagonist|antagonizing]] the [[estrogen receptor]] (ER) in the [[pituitary gland]], which reduces [[negative feedback]] by [[estrogen]] on the [[hypothalamic-pituitary-gonadal axis]], thereby increasing [[gonadotropin]] [[secretion]] and hence [[gonad]]al production of [[testosterone]].<ref name="pmid19204885" /> It is one of the two [[stereoisomer]]s of [[clomifene]], which itself is a non-[[racemic mixture]] of 38% [[zuclomifene]] and 62% enclomifene.<ref name="pmid19204885" /> Enclomifene is the (''E'')-[[enantiomer]] of clomifene, while zuclomifene is the (''Z'')-enantiomer.<ref name="Elks2014" /><ref name="MortonHall1999" /> Whereas zuclomifene is more [[estrogen]]ic, enclomifene is more [[antiestrogen]]ic.<ref name="pmid19204885" /> In accordance, unlike enclomifene, zuclomifene is [[antigonadotropic]] due to activation of the ER and is able to reduce testosterone levels in men to near-[[castration|castrate]] levels.<ref name="pmid19204885" /> As such, [[enantiopure]] enclomifene is more favorable than clomifene as a [[progonadotropin]] for the treatment of male hypogonadism.<ref name="pmid19204885" />

==See also==
* [[List of investigational hormonal agents#Estrogenics|List of investigational hormonal agents § Estrogenics]]

==References==
{{Reflist|2}}

==External links==
* [http://webcache.googleusercontent.com/search?q=cache:rTob_FmpvpUJ:adisinsight.springer.com/drugs/800019625+&cd=1&hl=en&ct=clnk&gl=us Enclomifene - AdisInsight]


{{Estrogen receptor modulators}}

[[Category:Enantiopure drugs]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Progonadotropins]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]


{{genito-urinary-drug-stub}}